AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer
- PMID: 21154126
AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer
Abstract
AT-9283 has been identified and developed by Astex Therapeutics via structure-based optimization of a ligand-efficient pyrazole-benzimidazole fragment. AT-9283 inhibits several important kinases, including the Aurora kinase A, Aurora kinase B, Janus kinase (Jak)2, Jak3 and Abl kinase. Studies using multiple solid tumor and leukemia cell lines have demonstrated the ability of AT-9283 to inhibit growth and survival of tumor cells, and the direct inhibition of these kinases has been demonstrated in cell-based systems. The in vivo antitumor activity of AT-9283 has also been demonstrated in human tumor xenograft models. Based on these preclinical studies, several clinical trials have been conducted in patients with hematological malignancies, such as leukemias, myelodysplastic syndrome, myeloproliferative disease, chronic myeloid leukemia, lymphomas and multiple myeloma, and also in patients with solid tumors. Although phase II clinical trials have not been completed, AT-9283 demonstrated good safety and efficacy in phase I clinical trials. Thus, AT-9283 has potential as a therapeutic agent in several patient populations through its different inhibitory activities.
Similar articles
-
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.J Med Chem. 2009 Jan 22;52(2):379-88. doi: 10.1021/jm800984v. J Med Chem. 2009. PMID: 19143567
-
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.Br J Haematol. 2010 Jul;150(1):46-57. doi: 10.1111/j.1365-2141.2010.08175.x. Epub 2010 May 7. Br J Haematol. 2010. PMID: 20507304
-
Aurora kinase inhibitors as anti-cancer therapy.Anticancer Drugs. 2010 Apr;21(4):339-50. doi: 10.1097/CAD.0b013e3283350dd1. Anticancer Drugs. 2010. PMID: 20016367 Review.
-
ENMD-2076 for hematological malignancies.Expert Opin Investig Drugs. 2012 May;21(5):717-32. doi: 10.1517/13543784.2012.668882. Epub 2012 Mar 8. Expert Opin Investig Drugs. 2012. PMID: 22397360 Review.
-
Is there a future for Aurora kinase inhibitors for anticancer therapy?Curr Opin Drug Discov Devel. 2009 Jul;12(4):533-42. Curr Opin Drug Discov Devel. 2009. PMID: 19562649 Review.
Cited by
-
Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma.Front Genet. 2022 Jul 8;13:917150. doi: 10.3389/fgene.2022.917150. eCollection 2022. Front Genet. 2022. PMID: 35873497 Free PMC article.
-
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment.Curr Med Chem. 2024;31(29):4657-4686. doi: 10.2174/0109298673277543231205072556. Curr Med Chem. 2024. PMID: 38204232 Review.
-
The extracellular and transmembrane domains of the γC and interleukin (IL)-13 receptor α1 chains, not their cytoplasmic domains, dictate the nature of signaling responses to IL-4 and IL-13.J Biol Chem. 2012 Sep 14;287(38):31948-61. doi: 10.1074/jbc.M112.348896. Epub 2012 Jul 24. J Biol Chem. 2012. PMID: 22829596 Free PMC article.
-
Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.J Gastrointest Cancer. 2015 Dec;46(4):380-9. doi: 10.1007/s12029-015-9761-9. J Gastrointest Cancer. 2015. PMID: 26346504
-
Inhibitors of One or More Cellular Aurora Kinases Impair the Replication of Herpes Simplex Virus 1 and Other DNA and RNA Viruses with Diverse Genomes and Life Cycles.Microbiol Spectr. 2023 Feb 14;11(1):e0194322. doi: 10.1128/spectrum.01943-22. Epub 2022 Dec 20. Microbiol Spectr. 2023. PMID: 36537798 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous